Clinical Trials
15 trialsNCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT03940235 2023-06-28
RADIOSA
European Institute of Oncology
Phase 2 Unknown
NCT03845751 2023-01-12
ENHANCE
Institut Mutualiste Montsouris
Phase 2 Unknown
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT03879122 2022-10-26
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2/3 Unknown
NCT05382182 2022-05-19
Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021
Sohag University
Unknown
NCT03061643 2022-03-08
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Samsung Medical Center
Phase 2 Unknown
NCT05188911 2022-01-12
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Fudan University
Unknown
NCT03119857 2021-08-18
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Göteborg University
Phase 3 Unknown
NCT04248621 2021-07-29
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Wonju Severance Christian Hospital
Phase 4 Unknown
NCT04599699 2020-10-23
SBRT
Changhai Hospital
Phase NA Unknown
NCT04489745 2020-07-28
Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
VA Greater Los Angeles Healthcare System
Phase 2 Unknown
NCT01978873 2016-05-04
SensiCab
Örebro University, Sweden
Phase 3 Unknown
NCT00967954 2014-01-10
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT00110162 2013-08-07
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown